The M&A boom of 2025 is just getting started - and here are 5 takeover targets
Stock investors may look back at 2025 as the year of the takeover - one that delivered sizeable gains. "It's going to be a big year," Calamos Investments senior portfolio manager Brandon Nelson ...
Viking Therapeutics initiated with a Neutral at Citi
Citi analyst David Lebowitz initiated coverage of Viking Therapeutics (VKTX) with a Neutral rating and $38 price target Viking’s VK2735 is an ...
The Pharma Letter16h
Viking sails ahead with pivotal trial and billion dollar cash pile
San Diegan biotech Viking Therapeutics (Nasdaq: VKTX) has announced plans to initiate late-stage clinical trials for its ...
Investor's Business Daily on MSN16h
Viking Therapeutics Plunged 6% On Its Earnings Report. Here's Why.
Viking Therapeutics stock plunged early Thursday on an earnings report that included mostly incremental updates for its ...
Viking Therapeutics Reports Q4 2024 Financial Results, Advances VK2735 Trials
Viking Therapeutics ( VKTX, Financials) reported its fourth-quarter and full-year 2024 financial results, highlighting ...
Viking Therapeutics price target raised to $125 from $122 at Raymond James
Raymond James analyst Steven Seedhouse raised the firm’s price target on Viking Therapeutics (VKTX) to $125 from $122 and keeps a Strong Buy ...